<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01805362</url>
  </required_header>
  <id_info>
    <org_study_id>08-API-03</org_study_id>
    <nct_id>NCT01805362</nct_id>
  </id_info>
  <brief_title>RAS Blockade at Bedtime Versus on Awakening for Aldosterone Breakthrough</brief_title>
  <acronym>IRAB2</acronym>
  <official_title>RAS Blockade at Bedtime Versus on Awakening for the Prevention of Aldosterone Breakthrough</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective:

      To show that the frequency of aldosterone breakthrough is lower when RAS blockers are given
      at bedtime compared to on awaking, and to analyze the determinants and consequences of
      aldosterone breakthrough.

      Duration of the study: Inclusion 2 years, follow-up one year, total 3 years Design:
      prospective, multicenter, randomized, controlled, open label, two parallel groups.

      Main selection criteria:

      Inclusion criteria

        -  Chronic kidney disease stage 3 to 4,

        -  ACEI (captopril, enalapril, or ramipril), and/or ARB (losartan, valsartan, or
           irbesartan) on awaking for at least three months,

        -  History of hypertension or proteinuria &gt; 0,5 g/24h or g/g créatininurie.

      Exclusion criteria

        -  Office blood pressure ≥ 160/100 mmHg,

        -  Anti-aldosterone (spironolactone, eplerenone) or potassium sparing diuretics (modamide,
           amiloride), or direct renin inhibitor.

      Evaluation criteria:

      Primary: Serum aldosterone levels at one year.

      Secondary:

        -  Serum aldosterone/renin ratio,

        -  24h urine aldosterone,

        -  Significant aldosterone breakthrough defined by a &gt;10% increase of serum aldosterone
           levels over baseline values,

        -  Aldosterone breakthrough defined by an increase of serum aldosterone levels over
           baseline values,

        -  HbA1c,

        -  Urinary albumin/creatinine ratio (UACR) on spot morning urine samples,

        -  Systolic home blood pressure (SBP),

        -  Estimated glomerular filtration rate (eGFR) using the MDRD equation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rational:

      Serum aldosterone levels may increase despite blockade of the renin angiotensin system (RAS)
      with angiotensin converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB).
      This aldosterone breakthrough might be associated with bad outcomes: left ventricular
      hypertrophy, proteinuria and progression of renal failure. Antihypertensive drugs are given
      either on awaking or at bedtime. RAS is stimulated during nighttime. RAS blockers and
      diuretics given on awaking may stimulate aldosterone synthesis, and favor aldosterone
      breakthrough.

      Objective:

      To show that the frequency of aldosterone breakthrough is lower when RAS blockers are given
      at bedtime compared to on awaking, and to analyze the determinants and consequences of
      aldosterone breakthrough.

      Duration of the study: Inclusion 2 years, follow-up one year, total 3 years

      Design: prospective, multicenter, randomized, controlled, open label, two parallel groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum aldosterone levels at one year</measure>
    <time_frame>Level change between baseline and one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum aldosterone/renin ratio</measure>
    <time_frame>level change between baseline and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant aldosterone breakthrough Significant aldosterone breakthrough</measure>
    <time_frame>changes between baseline and one year</time_frame>
    <description>Significant aldosterone breakthrough defined by a &gt;10% increase of serum aldosterone levels over baseline values,</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>MORNING</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients continue to take their treatments (RAS blockers and diuretics) on awaking</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EVENING</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients take their treatments(RAS blockers and diurectics)at bedtime</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Randomization that determine the time of treatment</intervention_name>
    <arm_group_label>MORNING</arm_group_label>
    <arm_group_label>EVENING</arm_group_label>
    <other_name>Randomization determine if the treatment will be taken in the morning or in the evening without changing the treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic kidney disease stage 3 to 4,

          -  ACEI (captopril, enalapril, or ramipril), and/or ARB (losartan, valsartan, or
             irbesartan) on awaking for at least three months,

          -  History of hypertension or proteinuria &gt; 0,5 g/24h or g/g creatininuria,

          -  Adult with social security insurance,

          -  Informed consent signed.

        Exclusion Criteria:

          -  Office blood pressure ≥ 160/100 mmHg,

          -  Pathology with life expectancy &lt; 1 year,

          -  Anti-aldosterone (spironolactone, eplerenone) or potassium sparing diuretics
             (modamide, amiloride), or direct renin inhibitor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent ESNAULT, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nice University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincent ESNAULT, MD</last_name>
    <email>esnault.v@chu-nice.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>delphine DEL CONT</last_name>
    <email>delcont.d@chu-nice.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Nephrology, Nice University Hospital</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>vincent Esnault, MD</last_name>
      <email>esnault.v@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent Esnault, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2013</study_first_submitted>
  <study_first_submitted_qc>March 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2013</study_first_posted>
  <last_update_submitted>September 14, 2016</last_update_submitted>
  <last_update_submitted_qc>September 14, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

